A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sanjeev Pathak, MD
Alkermes, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
44 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Alkermes Investigational Site
Gatineau, Canada
- Alkermes Investigational Site
Halifax, Canada
- Alkermes Investigational Site
Penticton, Canada
- Alkermes Investigational Site
Québec, Canada
- Alkermes Investigational Site
Berlin, Germany
- Alkermes Investigational Site
Berlin, Germany
- Alkermes Investigational Site
Hanover, Germany
- Alkermes Investigational Site
Oranienburg, Germany
- Alkermes Investigational Site
Schwerin, Germany
- Alkermes Investigational Site
Stralsund, Germany
- Alkermes Investigational Site
San Juan, Puerto Rico
- Alkermes Investigational Site
San Juan, Puerto Rico
- Alkermes Investigational Site
Birmingham, Alabama, United States
- Alkermes Investigational Site
Colton, California, United States
- Alkermes Investigational Site
Garden Grove, California, United States
- Alkermes Investigational Site
Los Angeles, California, United States
- Alkermes Investigational Site
Oakland, California, United States
- Alkermes Investigational Site
Oceanside, California, United States
- Alkermes Investigational Site
Pico Rivera, California, United States
- Alkermes Investigational Site
San Gabriel, California, United States
- Alkermes Investigational Site
Colorado Springs, Colorado, United States
- Alkermes Investigational Site
Bradenton, Florida, United States
- Alkermes Investigational Site
Fort Myers, Florida, United States
- Alkermes Investigational Site
Melbourne, Florida, United States
- Alkermes Investigational Site
North Miami, Florida, United States
- Alkermes Investigational Site
Oakland Park, Florida, United States
- Alkermes Investigational Site
Winter Haven, Florida, United States
- Alkermes Investigational Site
Smyrna, Georgia, United States
- Alkermes Investigational Site
Hoffman Estates, Illinois, United States
- Alkermes Investigational Site
Flowood, Mississippi, United States
- Alkermes Investigational Site
Saint Charles, Missouri, United States
- Alkermes Investigational Site
St Louis, Missouri, United States
- Alkermes Investigational Site
Princeton, New Jersey, United States
- Alkermes Investigational Site
New York, New York, United States
- Alkermes Investigational Site
High Point, North Carolina, United States
- Alkermes Investigational Site
Canton, Ohio, United States
- Alkermes Investigational Site
Portland, Oregon, United States
- Alkermes Investigational Site
Memphis, Tennessee, United States
- Alkermes Investigational Site
DeSoto, Texas, United States
- Alkermes Investigational Site
Wichita Falls, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2014
- Primary completion
- 30 Sept 2016
- Completion
- 31 Oct 2016
- Last update posted
- 14 Aug 2019
- Registered enrollment
- 407
- Registry id
- NCT02218008
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.